(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...

Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...

The proportion of patients who have been diagnosed with cancer at an early stage in England is at its highest ever level ...

Immuneering Corporation (IMRX) stock gains as company announces positive data for pancreatic cancer treatment and plans to expand its mid-stage program. Read more here.

Shares of Immuneering Corporation (NASDAQ:IMRX) surged 55% following the release of encouraging data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The Cambridge-based ...

Deep faith powered the superhero perseverance that drove Jason Potsander. Now, his three kids have inherited his love of ...

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

Richard Hays, who served as the dean of the Duke Divinity School from 2010 to 2015, died at age 76 at his home in Nashville, ...

Richard Hays, a renowned New Testament scholar and former dean of Duke Divinity School known for his influential books on ...

Researchers have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer patients.

Researchers from the University of Michigan have developed a way of detecting circulating tumor cells in the bloodstream of ...

Former Atlantic County Commissioner John Carman, 66, a veterans' advocate, gun rights proponent and motorcycle aficionado, ...